Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3101-3107

  Martin, Ludmila Katherine ^a   Wei, Lai ^b   Trolli, Elizabeth ^a   Bekaii Saab, Tanios ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Biomarker; CA19 9; Pancreas cancer; Prognostic

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; GEMCITABINE; TUMOR MARKER;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EARLY CANCER; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT FAILURE; TUMOR DIFFERENTIATION; ADENOCARCINOMA; CANCER STAGING; FEMALE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84880315637     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0278-9     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300. Published on 20100707. doi: 10.3322/caac.20073.
2. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-77. doi: 10.1001/jama.297.3.267.
3. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019-26. doi: 10.1001/jama.299.9.1019.
4. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073-81. doi: 10.1001/jama.2010.1275.
5. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002;94:902-10.
6. Colucci G, Labianca R, Di Costanzo F et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645-51. Published on 20100301. doi: 10.1200/JCO.2009.25.4433.
7. Cunningham D, Chau I, Stocken DD et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27: 5513-8. Published on 20091026. doi: 10.1200/JCO.2009.24.2446.
8. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946-52. doi: 10.1200/JCO.2005.05.1490.
9. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212-7. doi: 10.1200/JCO.2006.09.0886.
10. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-16. doi: 10.1200/JCO.2005.06.023.
11. Muller MW, Friess H, Koninger J, et al. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg. 2008;195:221-8. doi: 10.1016/j.amjsurg.2007.02.026.
12. Oettle H, Richards D, Ramanathan RK et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639-45. Published on 20050808. doi: 10.1093/annonc/mdi309.
13. Poplin E, Feng Y, Berlin J et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-85. Published on 20090706. doi: 10.1200/JCO.2008.20.9007.
14. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science. 1981;212:53-5.
15. Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350-5.
16. Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501-3.
17. Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897-902. doi: 10.1200/JCO.2005.05.3934.
18. Glenn J, Steinberg WM, Kurtzman SH, et al. Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol. 1988;6:462-8.
19. Satoi S, Yanagimoto H, Toyokawa H, et al. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas. 2011;40:426-32. doi: 10.1097/MPA.0b013e3182056b1c.
20. Zhang S, Wang YM, Sun CD, et al. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol. 2008;14:3750-3.
21. Waraya M, Yamashita K, Katagiri H et al. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol. 2009;16:1231-40. Published on 20090305. doi: 10.1245/s10434-009-0415-7.
22. Berger AC, Meszoely IM, Ross EA et al. Undetectable preoperative levels of serum CA19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004;11:644-49. Published on 20040614. doi: 10.1245/ASO.2004.11.025.
23. Sperti C, Pasquali C, Catalini S, et al. CA19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol. 1993;52:137-41.
24. Smith RA, Bosonnet L, Ghaneh P et al. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg. 2008;25:226-32. Published on 20080624. doi: 10.1159/000140961.
25. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994;69:515-9.
26. Motoi F, Rikiyama T, Katayose Y et al. Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines. Ann Surg Oncol. 2011;18:371-9. Published on 20100915. doi: 10.1245/s10434-010-1311- x.
27. Berger AC, Garcia Jr M, Hoffman JP et al. Postresection CA19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26:5918-22. Published on 20081124. doi: 10.1200/JCO.2008.18.6288.
28. Hata S, Sakamoto Y, Yamamoto Y et al. Prognostic impact of postoperative serum CA19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2011. Published on 20110824. doi: 10.1245/s10434-011-2020-9.
29. Kondo N, Murakami Y, Uemura K et al. Prognostic impact of perioperative serum CA19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2010;17:2321-9. Published on 20100325. doi: 10.1245/s10434-010-1033-0.
30. Yoo T, Lee WJ, Woo SM et al. Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81:e623-30. Published on 20110519. doi: 10.1016/j.ijrobp.2011.02.063.
31. Micke O, Bruns F, Kurowski R, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:90-7.
32. Ziske C, Schlie C, Gorschluter M et al. Prognostic value of CA19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003;89:1413-7. doi: 10.1038/sj.bjc.6601263.
33. Ko AH, Hwang J, Venook AP et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93:195-9. doi: 10.1038/sj.bjc.6602687.
34. Wong D, Ko AH, Hwang J, et al. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008;37:269-74. doi: 10.1097/MPA.0b013e31816d8185.
35. Halm U, Schumann T, Schiefke I, et al. Decrease of CA19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82:1013-6. doi: 10.1054/bjoc.1999.1035.
36. Hammad N, Heilbrun LK, Philip PA, et al. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia Pac J Clin Oncol. 2010;6:98-105. doi: 10.1111/j.1743-7563.2010.01290.x.
37. Rothenberg ML, Abbruzzese JL, Moore M, et al. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996;78:627-32. doi: 10.1002/(SICI)1097-0142(19960801)
38. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47. doi: 10.1016/j.ejca.2008.10.026.
39. You DD, Lee HG, Heo JS et al. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Surg. 2009;13:1699-706. Published on 20090707. doi: 10.1007/s11605-009-0969-5.
40. Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol. 2000;73:212-8.
41. Montgomery RC, Hoffman JP, Riley LB, et al. Prediction of recurrence and survival by post-resection CA19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997;4:551-6.